Aevi Genomic Medicine, Inc.
|Number of Estimates|
Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.
Market Cap: 8.48 Million
Primary Exchange: NASDAQ
Shares Outstanding: 64.8 Million
Float: 41.4 Million
Sector: Health Technology
Short Interest (Jan 12, 2018): 238 Thousand
Longest drawdown: 1710 trading days
From: 2015-09-18 To: 2019-11-12
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|